Naropin (ropivacaine) is the latest addition to AstraZeneca's local anaesthetic portfolio.

Naropin is currently indicated for surgical anaesthesia via the epidural and intrathecal (spinal) routes of administration, major nerve blocks and field block infiltration. It is also indicated for acute pain management via the epidural route and also field blocks, intra-articular injection and continuous peripheral nerve block.

First launched in 1996, Naropin is the world's first enantiomerically pure local anaesthetic (an S-form enantiomer), and is now available in over 30 countries, including the USA.